On March 24, 2026, Ensysce Biosciences, Inc. announced the resignation of Lee Rauch from its Board of Directors, effective immediately. Ms. Rauch, who served on the Audit Committee and Compensation Committee, expressed her disagreement with the company's recent decisions regarding fiscal responsibilities and compensation packages for key management. The Board approved a three-month severance package for three managers and increased the Chief Financial Officer's retention package from six to nine months. The total cost of these measures is approximately $205,475. Ms. Rauch voted against these packages, indicating a potential rift within the board regarding strategic decisions. The company is currently exploring strategic alternatives to enhance its business operations and maintain enterprise value. This leadership change and the accompanying compensation adjustments may signal internal challenges and could impact investor confidence in the company's governance and strategic direction.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.